 Multi-year data, with up to five years of follow up, show sustained expression of FVIII in more than 90 of participants, in addition to improved annual bleeding and infusion rates Data shared during an oral presentation at ASH 2022 PHILADELPHIA, Dec. 12, 2022 GLOBE NEWSWIRE Spark Therapeutics, a member of the Roche Group SIX: ... The post Spark Therapeutics Announces Updated Phase 12 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophil... 